Cagrilintide
Cagrilintide is a long-acting lipidated amylin receptor agonist and modified amylin analog. Preclinical research explores its effects on appetite suppression, satiety signaling, and metabolic regulation.
Key Research Areas
- • Studied as a long-acting amylin receptor agonist for potent appetite suppression and enhanced satiety.
- • Investigated for reduction of gastric emptying and modulation of energy intake and food reward pathways.
- • Explored for weight management and improvement of metabolic parameters in obesity and type 2 diabetes models.
Product Specifications
| Product |
Cagrilintide |
| CAS Number |
1415456-99-3 |
| Molecular Formula |
C194H312N54O59S2 |
| Molar Mass |
~4409 g/mol |
| Sequence |
{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (Disulfide bridge: Cys³–Cys⁸) |
| Synonyms |
Cagrilintide; AM833; long-acting amylin analog |
| Purity |
≥99% (HPLC) |
| Form |
Lyophilized powder |
| Storage |
−20°C (−4°F) long-term; 2–8°C (36–46°F) reconstituted |
| Solubility |
Bacteriostatic water for laboratory use |
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.
